Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Gajewski

Showing results (71-80 of 236) with videos related to

Pageof 24
Sort By:
Journal of Immunological Methods|January 8, 2008
Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cellsYuanyuan Zha, Ramila Shah, Frederick Locke, et al.
Science (New York, N.Y.)|March 24, 2018
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategiesLaurence Zitvogel, Yuting Ma, Didier Raoult, et al.
European Journal of Immunology|September 16, 2008
Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cellsCandace M Cham, Gregory Driessens, James P O'Keefe, et al.
Cell Research|December 17, 2016
Innate immune signaling and regulation in cancer immunotherapyLeticia Corrales, Vyara Matson, Blake Flood, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2004
Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cellsJames P O'Keefe, Kelly Blaine, Maria-Luisa Alegre, et al.
The Journal of Experimental Medicine|November 7, 2012
Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivoYan Zheng, Yuanyuan Zha, Gregory Driessens, et al.
The Journal of Clinical Investigation|July 2, 2016
The host STING pathway at the interface of cancer and immunityLeticia Corrales, Sarah M McWhirter, Thomas W Dubensky, et al.
Current Opinion in Immunology|December 28, 2010
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironmentThomas F Gajewski, Mercedes Fuertes, Robbert Spaapen, et al.
Investigational New Drugs|November 16, 2012
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanomaTara C Gangadhar, Joseph I Clark, Theodore Karrison, et al.
Cancer Immunology, Immunotherapy : CII|December 5, 2008
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanomaIlyssa O Gordon, Takisha Wade, Kevin Chin, et al.
Pageof 24

Showing results (71-80 of 236) with videos related to

Sort By:
Pageof 24
Journal of Immunological Methods|January 8, 2008
Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cellsYuanyuan Zha, Ramila Shah, Frederick Locke, et al.
Science (New York, N.Y.)|March 24, 2018
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategiesLaurence Zitvogel, Yuting Ma, Didier Raoult, et al.
European Journal of Immunology|September 16, 2008
Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cellsCandace M Cham, Gregory Driessens, James P O'Keefe, et al.
Cell Research|December 17, 2016
Innate immune signaling and regulation in cancer immunotherapyLeticia Corrales, Vyara Matson, Blake Flood, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2004
Formation of a central supramolecular activation cluster is not required for activation of naive CD8+ T cellsJames P O'Keefe, Kelly Blaine, Maria-Luisa Alegre, et al.
The Journal of Experimental Medicine|November 7, 2012
Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivoYan Zheng, Yuanyuan Zha, Gregory Driessens, et al.
The Journal of Clinical Investigation|July 2, 2016
The host STING pathway at the interface of cancer and immunityLeticia Corrales, Sarah M McWhirter, Thomas W Dubensky, et al.
Current Opinion in Immunology|December 28, 2010
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironmentThomas F Gajewski, Mercedes Fuertes, Robbert Spaapen, et al.
Investigational New Drugs|November 16, 2012
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanomaTara C Gangadhar, Joseph I Clark, Theodore Karrison, et al.
Cancer Immunology, Immunotherapy : CII|December 5, 2008
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanomaIlyssa O Gordon, Takisha Wade, Kevin Chin, et al.
Pageof 24